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The objective of this study was to assess the performance of a lung-specific health status measure in patients with 
chronic obstructive pulmonary disease (COPD). We used the Respiratory Quality of Life Questionnaire (RQLQ), a 
modification of an Australian questionnaire intended for asthma patients and adapted in this study to fit patients 
with COPD also. For comparison we chose the general health profile measure Short Form 36 (SF-36). 
We assessed the five RQLQ scales and eight SF-36 scales for reliability, validity and responsiveness in 59 
outpatients attending a Norwegian hospital for COPD. Statistical analysis included internal consistency, test-retest 
reliability and convergent validity between the two questionnaires. Responsiveness was assessed in patients reporting 
global change in health status over 1 year. 
All scales of the RQLQ showed good internal consistency (Cronbach’s a=0.85-0.94) and test-retest reliability 
(intraclass correlation coefficient=0.86-0.94), as did the SF-36 scales (a=0.66-0.90 and intraclass correlation 
coefficient=0.60-0.86). Pearson correlations between scales with similar items ranged from 0.54 to 0.76, supporting 
the construct validity of both questionnaires. The RQLQ had responsive scales, showing significant changes in the 
expected direction over 1 year. 
We conclude that the RQLQ showed an acceptable reliability, construct validity and responsiveness in COPD 
patients, encouraging further use of this questionnaire. 
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Introduction 
Health status has become an increasingly important consid- 
eration in evaluating the impact of chronic disease, includ- 
ing asthma and chronic obstructive pulmonary disease 
(COPD). Several validated disease-specific questionnaires 
are available for the assessment of health status in patients 
with pulmonary disease (l-6). These questionnaires were 
developed for use in different populations, e.g. respiratory 
disease in general, including asthma and COPD (1,3), or 
more specifically for asthma patients (4,6). 
We wanted to translate and adopt a lung-specific ques- 
tionnaire for use in our COPD patients. The questionnaire 
ideally should have the following properties: short, self- 
administered, easy to comprehend, quick to fill in and 
easy to score with documented reliability, validity and 
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responsiveness. Existing measures for use in patients with 
COPD did not fulfill these requirements; they were consid- 
ered too long, only validated in a hospital setting or were 
interviewer-administered (1,3). 
We then investigated the content and wording of other 
respiratory health status questionnaires, to assess their 
feasibility for use in patients with COPD. We felt that the 
items of the Australian Asthma Quality of Life Question- 
naire (AQLQ) (6) could be adapted for use in COPD. Thus, 
instead of developing a new questionnaire, we assessed 
whether this modified AQLQ was applicable and had the 
desired psychometric properties in patients with COPD. We 
renamed this modified questionnaire the Respiratory 
Quality of Life Questionnaire (RQLQ) and chose for com- 
parison the general health status measure Short Form 36 
(SF-36) (7,8). This measure is extensively used in a variety 
of countries and in many different chronic conditions. The 
psychometric properties of SF-36 in patients with COPD 
are not yet well documented, although the instrument has 
been evaluated in patients with various chronic lung dis- 
eases in Canada (9) and more recently in COPD patients in 
the U.S.A. (lo), Australia (1 I), Spain (12), and the U.K. 
(13). 
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The objective of our study was to assess the performance 
of the RQLQ in patients with COPD. We investigated 
the reliability, validity and responsiveness of this question- 
naire, using the widely used generic SF-36 measure for 
comparison. 
Materials and Methods 
PATIENTS 
All patients with COPD seen at the outpatient clinic at the 
Central Hospital of Akershus (ICD-9 code 496) from 1 
January 1994 to 10 April 1995 and aged 18-67 years were 
possible candidates for the study; 198 patients in total. We 
reviewed medical records for all candidates. Inclusion cri- 
teria were forced expiratory volume in 1 set (FEV,) _< 70% 
of predicted, improvement after inhalation of &agonist 
_< 15% in FEV, or unknown in previous tests. Patients were 
excluded if they had a history of ischemic heart disease, 
intermittent claudication, severe musculoskeletal diseases 
or other disabling disorders. We contacted candidates by 
telephone and asked them to participate in the study, 
which was approved by the regional medical ethics review 
committee. 
After initial screening, 77 patients were eligible of whom 
six could not be reached, seven refused to participate, and 
five withdrew from the study. Fifty-nine patients were 
included and completed the study. When comparing data 
from the initial screening of medical records for eligibility 
to the study, participants (n=59) had significantly better 
spirometry than non-participants (n= 18) mean FEV, (% 
pred.) 53 and 40 respectively; P=O.O02. There was no 
significant difference in age for the two groups. 
HEALTH STATUS ASSESSMENT 
Respiratory Qualify of Life Questionnaire 
The Asthma Quality of Life Questionnaire (AQLQ) was 
developed in Australia and has previously been evaluated in 
asthma patients in Australia (6,14), Spain (15); U.K. (5) 
and recently in the U.S.A. (16,17). The AQLQ question- 
naire is self-administered and consists of 20 items scored on 
a five-point Likert scale. The items include symptoms, 
limitations and feelings during the last 4 weeks. Scores are 
aggregated to a total score and four subscales: breathless- 
ness, mood, concerns and social. Scores range from 0 (least 
problems) to 10 (maximal problems or symptoms). The 
instrument is brief and easy to score both manually and 
with a computer (6). The Norwegian translation of the 
questionnaire was made independently by two physicians 
(P.S. and K.S.) who, after discussion, arrived at a consensus 
version, Later, this consensus version was translated 
back into English by an English physician fluent in 
Norwegian (M.D.). Comparison of the back-translation 
with the original English version revealed virtually no 
discrepancies. 
As we intended to use this questionnaire in patients with 
COPD, and the original AQLQ questionnaire contains the 
word asthma on several occasions, we modified the ques- 
tionnaire by substituting my lung disease for asthma when- 
ever it appeared, except in the last item where we 
substituted asthma medication for asthma spray. This was 
because the latter term is commonly used in all types of 
asthma and COPD and also because of the frequent use of 
dry powder inhalers in Norway. By introducing this modi- 
fication of the questionnaire, it was hoped that the ques- 
tionnaire was suitable for use in both COPD and asthma 
patients without altering its content or properties. To avoid 
confusion between versions and to underline that the modi- 
fied AQLQ was not just a measure for asthma patients, we 
named the new questionnaire the Respiratory Quality of 
Life Questionnaire (RQLQ; see Appendix A). 
Short Fovm 36 (SF-36) 
The general health status questiomraire SF-36 is intended to 
assess aspects of health important to all patients. SF-36 was 
developed in the U.S.A. and assesses eight dimensions of 
health including physical function, role limitations due to 
physical problems, bodily pain, general health, vitality, 
social function, role limitations due to emotional problems 
and mental health (7). The scales corresponding to these 
dimensions were scored from 0 (lowest level of functioning) 
to 100 (highest level of functioning). In addition, physical 
and mental health summary measures were scored using 
standard algorithms (18). 
The SF-36 has been extensively validated in patients and 
general populations (7,8). However, there has been limited 
experience of its use among subjects with COPD (9-13). We 
used the Norwegian standard SF-36 version 1.0, as trans- 
lated in the International Quality of Life Assessment 
(IQOLA) project (19) to assess health status over the last 4 
weeks. 
DATA COLLECTION 
The patients received a questionnaire, including the RQLQ 
and SF-36 questionnaires, to be filled in at home the day 
before an outpatient consultation. During the consultation 
they received an additional questionnaire, had pulmonary 
function testing, an arterial puncture for blood gas analysis 
and an extensive interview and medical consultation. For 
10 days following the consultation the patients metered 
peak expiratory flow (PEF) in the morning and evening 
before taking medication. They were asked to fill in the 
same questionnaire on day 10 as before the consultation. 
One year later the patients again received the same 
questionnaire, which was filled in at home and returned by 
mail. Two reminders were sent. The order of presentation 
of the instruments within the questionnaires was the same 
throughout the study. 
LUNG FUNCTION AND EXERCISE CAPACITY 
ASSESSMENT 
Our definition of COPD in this study includes spirometric 
criteria. The purpose of lung function testing here was to 
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describe the patient population and ensure that our 
material consisted of patients compatible with our defini- 
tion of COPD. Exercise testing was also carried out to 
describe the patient population. 
On the day of consultation, FEV,, forced vital capacity 
(FVC) and carbon monoxide transfer factor (nC0 were 
determined using a pneumotachograph (Jaeger, Wiirzburg, 
Germany). RCO was determined by the single breath 
method. The patients were instructed not to take 
&agonists in the morning of that day, and no inhalers 
during the last 4 h prior to testing. Reversibility was 
assessed by measuring FEV, before and 15 min after 
inhalation of 5 mg salbutamol administered by nebulizer 
(Medic Aid Ltd, West Sussex, U.K.). European Commu- 
nity for Coal and Steel values were used as reference (20). 
For PEF measurements at home, the patients used a 
Vitalograph peak flow meter (Vitalograph, Buckingham, 
U.K.) after standardized instruction at the outpatient clinic. 
For spirometry and peak flow measurements the best of 
three measurements was recorded. Exercise capacity was 
assessed using a 6-min walking distance test, using a 
standardized protocol for instruction and encouragement. 
The same technician (O.N.) administered all lung function 
and exercise tests. 
STATISTICAL ANALYSIS 
Reliability 
Internal consistency reliability was assessed using 
Cronbach’s a (21). Test-retest reliability was assessed after 
intervals of 10 days and 1 year, using Spearman’s rank 
correlation (p) and an intraclass correlation coefficient 
(ICC) (22,23). 
Validity 
Construct validity for the health status scales was assessed 
comparing associations between scales at baseline with a 
priori predicted associations. Based on previous literature 
(6,7) and content analysis of the scales, we hypothesized 
which scales would be similar in the two instruments. 
1. The breathlessness subscale of the RQLQ, with items on 
physical symptoms and activity restrictions, was 
expected to correlate well with the physical functioning, 
role-physical and general health scales of the SF-36, and 
to show a lower correlation with the SF-36 mental health 
scale. 
2. The RQLQ concerns subscale deals with items relating 
to role limitation and concern for deterioration and 
would be expected to correlate with SF-36 role-physical, 
role-emotional and general health scales. 
3. The association between RQLQ mood, containing items 
relating to mental symptoms and frustration, would be 
expected to be good with the SF-36 vitality and mental 
health subscales. 
4. The RQLQ social subscale, focusing on interference with 
social life, role limitation and activity restrictions, would 
be expected to have the strongest association with the 
SF-36 physical functioning, role-physical and social 
functioning scales. 
Results are presented in a multitrait-multimethod matrix 
(24). For similar scales, the correlation would be expected 
to be substantial @=0.61-0.80), using nomenclature from 
work on agreement statistics (25). Associations between 
diverging scales would be expected to be fair (p=O.21-0.40) 
to moderate (p=O.41-0.60). Little association here 
(heterotrait-homomethod correlations) would support con- 
struct validity. Completion rate was assessed only for the 
retest, which was filled in at home and returned by mail. 
Responsiveness 
This was evaluated by comparing mean changes in health 
status scores between baseline and 1 year with a global 
rating of change as reported by the patients. The approach 
used is one of several suggested strategies for assessing 
responsiveness (22,23). The response to item 2 on the SF-36 
was used as a global rating of change: ‘Compared to one 
year ago, how would you rate your health in general now? 
(much better, somewhat better, about the same, somewhat 
worse, much worse)‘. The respondents were categorized as 
having a better, unchanged or worse health status, as 
reported in another study (13). For each category mean 
change in health status score, effect size [(mean baseline 
score-mean 1 year score)/sD baseline score] (22) and 
responsiveness statistic [(mean baseline score - mean 1 year 
score)/sr, change scores in patients with unchanged health 
status] (22,23,26) were calculated. Group comparison of 
change scores in patients with better, unchanged and worse 
global health status was analysed using Kruskal-Wallis 
test. 
For assessing stability of scores over time in patients 
reporting unchanged health status, we used Spearman’s 
rank correlation and an intraclass correlation coefficient, 
comparing scores at baseline and after 1 year (22). The 
Mann-Whitney U-test was used for comparison of baseline 
spirometry values for participants and non-participants. 
We used SPSS statistical software (SPSS, Chicago, IL, 
U.S.A.) for all analyses. 
Results 
SAMPLE AND RESPONSE 
Fifty-nine patients (34 men and 25 women) were included 
and completed the study. 
The participants’ mean (SD) age was 57.0 (9.1) years. The 
mean FEV, for the sample was 1.46 1, or 47% of predicted 
value for their age, height and gender. After inhalation of 
&agonist, mean FEV, increased to 54% of predicted value. 
Mean RCO/alveolar volume (VA) for the group was 65% 
of predicted, mean PAO, 9.4 kPa, mean 6-min walk dis- 
tance 503 m and mean heart rate at rest of 84 beats min- ‘. 
In the sample there were 10% never-smokers and 64% 
previous smokers. On average, the smokers and previous 
smokers had been smoking for 34 years. 
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TABLE 1. Health status dimension scores at the initial assessment 
Number 
of items n Mean SD Median % min % max 
RQLQ” 
Breathlessness 5 58 4.9 24 4.8 1.7 3.4 
Mood 5 55 3.9 2.4 3.5 5.5 0 
Concerns 7 55 4.7 2.5 4.6 1.7 1.7 
Social 7 59 4.5 2.7 4.6 5.1 3.4 
Total 20 55 4.6 2.3 4.4 0 0 
SF-36t 
Physical functioning 10 59 58.7 23.4 60 0 1.7 
Role-physical 5 59 33.3 34.8 25 42.4 8.5 
Bodily pain 2 59 64.0 27.6 62 0 25.4 
General health 5 59 42.2 22.8 40 5.0 1.7 
Vitality 4 59 49.7 21.9 45 3.4 1.7 
Social functioning 2 59 76.1 23.7 75 0 33.9 
Role-emotional 4 59 56.8 38.2 61 20.3 33.9 
Mental health 5 59 74.9 20.1 80 0 6.7 
*For the RQLQ, a higher score means more symptoms or worse function (range O-10). ?-For the 
SF-36, a higher score means less symptoms or better function (range O-100). % min, percentage of 
respondents with minimum possible score (floor); % max, percentage of respondents with maximum 
possible score (ceiling). 
HEALTH STATUS SCORES 
RQLQ and SF-36 scores are shown in Table 1, including 
the percentage of respondents giving the lowest (floor) and 
highest possible (ceiling) scores. The patients’ scores were 
spread throughout most of the possible range. The RQLQ 
scores did not concentrate at the floor or ceiling for any 
subscale. However, the SF-36 scale role-physical scores 
were concentrated at the floor (42%) and the social func- 
tioning (34%) and role-emotional (34%) scales were concen- 
trated at the ceiling. The mean SF-36 physical summary 
score was 36.3 (SD 9.5) and mental summary 49.7 (9,9), 
given as normalized standardized scores for comparison 
with a general American reference population with a mean 
Of 50 (SD 10) (18). 
The completion rate for the retest filled in at home, on 
average 14 days after the first questionnaire, was high for 
both questionnaires: the proportion of items completed was 
99.7% (RQLQ) and 98.9% (SF-36); the proportions of 
storable multi-item dimensions were 97.8% and 98.7%, 
respectively. The completion rate for the RQLQ total scale 
was 94.6%. / 
INTERNAL CONSISTENCY AND TEST-RETEST RESPONSIVENESS AND LONG-TERM 
RELIABILITY RELIABILITY 
The internal consistency reliability coefficient was high for 
all dimensions of the RQLQ (a=0.85-0.95) (Table 2). 
Test-retest reliability for the RQLQ was also high, as 
indicated by Spearman’s p and an ICC (Table 2). SF-36 
internal consistency reliability was high (a=0.76-0.90 for all 
scales except the role-emotional scale, ~~0.66; Table 2). 
After 1 year, three patients had died, one was excluded as 
he had developed severe hip problems, and two who were 
still alive did not respond. Thus, 53 of the 59 patients 
completed the questionnaire after 1 year. In patients 
reporting an improvement or a worsening on the global 
rating of change, mean changes in health status scores 
When item 5c (‘Didn’t do work or other activities as 
carefully as usual’) was left out, a for the role-emotional 
scale increased to 0.76. Test-retest reliability also was high, 
with Spearman’s p=O.59-0.88 for the eight scales, only with 
the role-emotional and social functioning scales below 0.75 
(Table 2). 
CONSTRUCT VALIDITY 
Multitrait-multimethod analysis shows correlations 
between subscales of the two health status measures (Table 
3). Subscales which, on the basis of item content, were 
hypothesized to correspond well are shown in bold face in 
Table 3. The hypothesized associations were generally 
among the highest, to a large extent confirming the hypoth- 
esis, although some of the other subscales also correlated 
well. Subscales of the RQLQ showed high correlations 
@=0,60-0.93); partly reflecting an overlap of subscale 
constructs (not shown). The internal correlations between 
scales of the SF-36 were, for most comparisons, somewhat 
lower. 
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TABLE 2. Internal consistency and test-retest reliability by dimension 
Internal consistency 






















0.86 0.89 0.86 
0.85 0.90 0.90 
0.91 0.90 0.93 
0.94 0.94 0.94 



















*Five patients showing trend in peak expiratory flow were excluded; ICC, intraclass correlation 
coefficient. 
TABLE 3. Multitrait-multimethod correlation matrix. Pearson’s correlation coefficients between 
subscales of the RQLQ and SF-36. Hypothesized high correlations from analysis of item and scale 
content are in bold face (comparable scales) 
RQLQ (n = 55-59) 












- 0.71 - 0.64 - 0.36 - 0.76 - 0.73 
- 0.60 - 0.66 - 0.44 - 0.71 - 0.71 
- 0.32 - 0.35 - 0.41 - 0.37 - 0.39 
- 0.52 - 0.61 - 0.47 - 0.64 - 0.63 
- 0.50 - 0.47 - 0.69 - 0.42 - 0.59 
- 0.39 - 0.52 - 0.49 - 0.54 - 0.54 
- 0.40 - 0.64 - 0.47 - 0.51 - 0.57 
- 0.35 - 0.59 - 0.73 - 0.42 - 0.56 
- 0.66 - 0.59 - 0.34 - 0.73 - 0.66 
- 0.34 - 0.59 - 0.76 - 0.43 - 0.58 
were in the expected directions both for the RQLQ 
and the SF-36 (Table 4). Change scores in the three 
groups were significantly different for most subscales 
(Table 4). 
Effect sizes and responsiveness statistics were higher for 
subscales of the RQLQ in patients reporting a change 
than for patients in the ‘unchanged’ group, except for the 
concerns subscale (Table 5). For SF-36 scales the par- 
ameters showed a similar pattern, although effect sizes and 
responsiveness statistics were generally lower than for 
RQLQ in patients showing improvement, and not as dis- 
tinct from the patients in the ‘unchanged’ group (Table 5). 
Test-retest reliability over 12 months in patients reporting 
unchanged health status on global rating of change was 
high for the RQLQ and generally lower for the SF-36 
(Table 6). 
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TABLE 4. Mean change in health status scores. A positive change score means improvement in health 
status (RQLQ) or deterioration (SF-36) 
Better 
Change (n) 
Global rating of change 
Unchanged Worse 
Change (n) Change (n) P-value* 






















- 3.40 (8) 
- 35.42 (8) 
- 10.56 (9) 
- 16.28 (8) 
- 7.50 (8) 
- 2.78 (9) 
- 4.17 (8) 
0.50 (8) 





- 0.19 (26) 
0.18 (21) 
4.07 (26) 
- 8.65 (26) 
- 7.85 (26) 
2.83 (26) 
- 0.58 (26) 
- 4.33 (26) 
- 1.92 (26) 
0.46 (26) 
- 0.79 (26) 
- 0.50 (26) 
- 0.42 (18) 
- 0.33 (18) 
- 0.52 (18) 
- 0.65 (18) 
- 0.38 (17) 
4.42 (18) 0.12 
13.89 (18) O,OOO4 
7.06 (18) 0.06 
8.59 (17) 0.02 
11.39 (18) 0.02 
9.72 (18) 0.05 
26.85 (18) 0.03 
5.33 (18) 0.33 
3.27 (17) 0.003 







TABLE 5. Responsiveness in patients after reported global rating of change in health status 
Global rating of change 
Better (n = 669) Unchanged (~~23-26) 
Effect Responsiveness Effect Responsiveness 





















0.90 1.31 0.03 0.05 - 0.17 - 0.27 
0.92 1.63 0.04 0.08 - 0.22 - 0.41 
1.13 2.45 0.35 0.75 - 0.14 - 0.31 
0.82 1.73 - 0.08 - 0.16 - 0.24 - 0.54 
1.09 2.49 0.08 0.21 - 0.18 - 0.43 
- 0.17 - 0.22 0.19 0.26 0.17 0.28 
- 1.14 - I.02 - O-23 - 0.25 0.47 0.39 
- 0.36 - 0.37 - 0.30 - 0.27 0.24 0.24 
- 0.86 - 1.35 0.14 024 0.36 0.75 
- 0.35 - 0.69 - 0.03 - 0.05 0.58 1.04 
- 0.12 - 0,18 - 0.20 - 0.27 0.38 0.60 
- 0.12 - 0.09 - 0.05 - 0.04 0.67 0.59 
0.02 0.03 0.03 0,03 0.24 0.34 
- 081 - 0.90 - 0.08 - 0.10 0.33 0.40 
0.04 0.06 - 0.06 - 0.07 0.57 0.74 
Discussion 
The CQPD patients in this study were sampied from a 
defined population of hospital outpatients. The representa- 
tiveness of the respondents can therefore be evaluated, in 
contrast to some previous validation studies (1,3,27). The 
respondents (77% of eligible patients) differed somewhat in 
spirometry values from non-participants as they had less 
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TABLE 6. Test-retest reliability over 12 months in patients 
reporting unchanged health status on global rating of 
change 


















0.81 0.80 25 
0.85 0.83 22 
0.87 089 26 
0.90 0.90 26 
048 0.93 22 
0.76 0.75 26 
0.55 0.58 26 
0.42 0.41 26 
0.69 0.81 26 
0.84 0.86 26 
0.55 0.74 26 
0.19 0.20 26 
0.40 0.61 26 
0.65 0.65 26 
0.49 0.67 26 
ICC, Intraclass correlation coefficient. 
severe disease. Importantly, patients above 67 years (the 
age of retirement for most Norwegians) were not included. 
The study group was reasonably representative for the 
target population, but one should be careful about 
generalizing to all patients with COPD. 
The Australian AQLQ has previously shown a very high 
internal consistency reliability for all four subscales among 
asthma patients (6,15-l 7) and in an Australian community 
sample (6) which was confirmed in our modified question- 
naire in COPD patients. The test-retest reliability in 
this study was high for all subscales, in agreement with 
Australian and American asthma patient data (6,16), with 
the lowest correlation for the breathlessness subscale, as 
previously reported (6). However the test-retest reliability 
was higher in this sample of stable COPD patients 
(ICC=O.86-0.94) than in stable asthma patients 
(ICC=O.61-0.80) (6) although this difference could be 
influenced by differences in the test-retest intervals (mean 
14 and 24 days, respectively). 
SF-36 also showed good internal consistency reliability 
(a=0.76-0.90) and test-retest reliability (ICC=O.71-0.86) 
except for the role-emotional scale. The internal consistency 
reliability of SF-36 is comparable with the findings of 
others, both in asthma patients (28), general populations 
(8,29-31) and in selected groups (32). Test-retest reliability 
for the SF-36 over 2 weeks was in line with the findings in 
two U.K. postal surveys in patients (30,33), including the 
finding of a low test-retest reliability for the role-emotional 
scale. When deleting item 5c in the analysis, the internal 
consistency reliability for the role-emotional scale in this 
study increased from 0.66 to 0.76. In spite of the sophisti- 
cated translation procedure in the IQOLA project (19), the 
wording of the item 5c of the SF-36 could have been 
improved. In later versions of the Norwegian SF-36, the 
wording of this item was modified. 
It has been suggested that health status measures can be 
used for comparisons at group level if reliability is above 
0.70 (34). All scales of both the RQLQ and SF-36 instru- 
ments, except SF-36 role-emotional, had internal consist- 
ency reliability over 0.70. For use at the individual patient 
level, it has been suggested that the bare minimum require- 
ment for reliability is 0.90, while 0.95 is desirable (34) 
although perhaps too stringent (22). For the RQLQ, two 
of four subscales plus the total scale reached 0.90, 
while only the physical functioning scale of the SF-36 
achieved this value. The total scale only of the RQLQ 
reached 0.95. 
The pattern of correlations between the two instruments 
confirmed what was expected from item content analysis. 
The associations expected to be high were among the 
highest observed, and similarly combinations with low 
expected associations were at the low end, supporting 
convergent and discriminant validity of the scales (35). 
Changes in health status scores over time were evaluated 
in groups of patients after their own direct reports of global 
change, as suggested (26) and used previously (13). One of 
the questions of the SF-36 questionnaire was used as a 
rating of global change and was assumed to have at least 
face validity for global change in health status. The 
observed change was not limited to a specific domain or 
component of health status. Most subscales showed 
changes in the expected directions, except for the SF-36 
role-emotional, mental health and accordingly mental com- 
ponent summary scores. The stability of scores in stable 
patients over 1 year was very good. 
Both the cross-sectional and longitudinal part of the 
study support the construct validity of the two measures. 
The data indicate that subscales of both measures are 
sensitive to clinical changes over time and therefore may 
encourage their further use. Both measures are short with a 
low respondent burden. The patients accepted these ques- 
tionnaires well, as demonstrated by the high completion 
rates. 
In this study we did not assess the weighting of items in 
the scoring models. It is possible that differences in lan- 
guage and culture could lead to some differences in health 
status scores between subjects studied in different countries, 
although we consider that such a difference would be small. 
To reduce these differences as much as possible, we used a 
translation-back-translation procedure in the translation 
process. 
Available health status questionnaires differ in content, 
with differences in the use of symptom, activity, functional 
limitation or emotional items. These differences stem in part 
from the use of different methods used for item generation, 
selection and refinement (36). In the field of respiratory- 
specific health status assessment there are no conventionally 
accepted procedures for the process of producing a scale, 
nor for the style of the eventual product (36). In this 
study the RQLQ performed well in a different patient group 
than the one for which it was initially developed. In 
conclusion, this study confirms that the RQLQ is a reliable 
instrument for the measurement of health status, has 
474 K. STAVEM ET AL. 
acceptable cross-sectional validity and is responsive to 
change, justifying its further use in COPD patients. 
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Appendix A 
RESPIRATORY QUALITY OF LIFE QUESTIONNAIRE 
1. I have been troubled by episodes of shortness of breath. 
2. I have been troubled by wheezing attacks. 
3. I have been troubled by tightness in the chest. 
4. I have been restricted in walking down the street on level ground or doing light housework because of my lung disease. 
5. I have been restricted in walking up hills or doing heavy housework because of my lung disease. 
6. I have felt tired or a general lack of energy. 
7. I have been unable to sleep at night. 
8. I have felt sad or depressed. 
9. I have felt frustrated with myself. 
10. I have felt anxious under tension or stressed. 
11. I have felt that my lung disease is preventing me from achieving what I want from life. 
12. My lung disease has interfered with my social life. 
13. I have been limited in going to certain places because they are bad for my lung disease. 
14. I have been limited in going to certain places because I have been afraid of getting an attack of breathlessness and not 
being able to get help. 
15. I have been restricted in the sports hobbies or other recreations I can engage in because of my lung disease. 
16. I have felt generally restricted. 
17. I have felt that my lung disease is controlling my life. 
18. I have been worried about my present or future health because of my lung disease. 
19. I have worried about my lung disease shortening my life. 
20. I have felt dependent on my asthma medication. 
Response options for each question as in the original AQLQ (14): not at all, mildly, moderately, severely, and very 
severely. Scoring as in the original AQLQ (14). 
